Physician profile
Thomas M Mccormack
NPI 1508821596
$2,871.39
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $196 · 2021: $78.14 · 2022: $1,043 · 2023: $452 · 2024: $85.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $435.19 | 2021-2023 | Proclaim |
| Si-Bone, INC. | $414.30 | 2019-2022 | |
| Medtronic USA, INC. | $401.15 | 2019-2020 | |
| Boston Scientific Corporation | $327.87 | 2019-2022 | |
| Stryker Corporation | $242.96 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $122.41 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $97.18 | 2019-2023 | Neuro Plating System |
| Cerapedics INC. | $80.12 | 2020-2023 | I-Factor Peptide Enhanced Bone Graft |
| Zimvie INC. | $79.75 | 2023-2024 | |
| Spr Therapeutics, INC | $74.00 | 2022-2024 | Sprint Pns System |
| Surgalign Spine Technologies, INC. | $70.26 | 2020-2022 | |
| Medtronic, INC. | $58.88 | 2022 | |
| Argenx US, INC. | $58.22 | 2023 | Vyvgart Hytrulo, Vyvgart |
| 4web, INC. | $56.83 | 2019 | |
| Integra Lifesciences Corporation | $55.51 | 2021-2023 | Codman Hakim, Duraseal Exact Spinal Sealant System, Codman Certas |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $54.09 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $47.97 | 2022-2023 | Andexxa |
| Lemaitre Vascular, INC. | $37.52 | 2023 | Anastoclip Gc 8cm (Medium) |
| Relievant Medsystems, INC. | $35.05 | 2022 | |
| Azurity Pharmaceuticals, INC. | $26.30 | 2023 | Gliadel |
| Ipsen Biopharmaceuticals, INC | $23.31 | 2024 | Dysport |
| Kowa Pharmaceuticals America, INC. | $22.72 | 2023 | Seglentis |
| Nevro Corp. | $19.96 | 2023 | Senza |
| Radius Health, INC. | $16.92 | 2021 | |
| Portola Pharmaceuticals, LLC | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mccormack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.